Methodological challenges of symptom management research in recurrent cancer

Cancer Nursing

Volumn 31, Issue 3, 2008, Pages 175-181

  Visovsky, Constance G ^a   Berger, Ann M ^a   Kosloski, Karl D ^b   Kercher, Kyle ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Aging; Comorbidity; Recurrent cancer; Symptom management; Treatment effects

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; CANCER SURVIVOR; COMORBIDITY; FUNCTIONAL STATUS; HUMAN; PRIORITY JOURNAL; RECURRENT CANCER; SAMPLING; SYMPTOMATOLOGY;

AGING; COMORBIDITY; DISEASE PROGRESSION; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; RESEARCH;

EID: 43249113091     PISSN: 0162220X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NCC.0000305727.50098.b5     Document Type: Article

References (36)

1. American Cancer Society. Cancer statistics, 2006. http://www.cancer.org/ docroot/stt/stt_0.asp. Accessed November 1, 2006.
2. Kirkova J, Davis MP, Tiernan E, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006;24(9):1459-1473.
3. Yancik R, Wesley MN, Ries LAG, Havlik RH, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885-892.
4. Yancik R, Wesley MN, Reis LA, et al. Comorbidity and age as predictors for early mortality of male and female colon carcinoma patients: a population based study. Cancer. 1998;82(11):2123-2134.
5. Ferrier M, Spuesens EB, Le Cessie S, Baatenburg de Jong RJ. Comorbidity as a major risk factor for mortality & complications in head and neck surgery. Arch Otolaryngol Head Neck Surg. 2005;131:27-32.
6. Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002;112:1988-1996.
7. Piccirillo JF, Spitznagel EL, Vermani N, Costas I, Schnitzler M. Comparison of comorbidity indicies for patients with head and neck cancer. Med Care. 2004;42(5):482-486.
8. Mandelblatt JS, Bierman AS, Gold K, et al. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res. 2001;36(6):1085-1107.
9. Silliman RA, Lash TL. Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Med Care. 1999;37(4):339-349.
10. Klabunde CN, Reeve BB, Harlan LC, Davis WW, Potosky AL. Do patients consistently report comorbid conditions over time? Results from the prostate cancer outcomes study. Med Care. 2005;43(4):391-400.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
12. Selim AJ, Fincke G, Ren XS, et al. Comorbidity assessments based on patient report: results from the Veterans Health Study. J Ambul Care Manage. 2004;27(3):281-295.
13. Linn BS, Linn MW, Gurel L. Cumulative Illness Rating Scale. J Am Geriatr Soc. 1968;16(5):622-626.
14. Rozzini R, Frisoni GB, Ferrucci L, et al. Geriatric Index of Comorbidity: validation and comparison with other measures of comorbidity. Age Ageing. 2002;31(4):277-285.
15. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36(4):428-434.
16. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003;49(2):156-163.
17. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol. 2003;56:221-229.
18. Flemming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999;37(6):601-614.
19. Alamo J, Shahjahan M, Lazarus HM, de Lima M, Giralt SA. Comorbidity indices in hematopoietic cell transplantation: a new report card. Bone Marrow Transplant. 2005;36(6):475-479.
20. National Cancer Institute. Cancer Therapy Evaluation Program, National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) v 3.0. 2006. http://webapps.ctep.nci.nih.gov. Accessed November 1, 2006.
21. Varricchio CG, Sloan JA. The need for and characteristics of randomized, phase III trials to evaluate symptom management in patient with cancer. J Natl Cancer Inst. 2002;94(16):1184-1185.
22. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13(3):595-605.
23. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88(9):2164-2171.
24. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570-579.
25. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000;89(7):1634-1646.
26. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326-1336.
27. de Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990;62(6):1034-1038.
28. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory. Behav Sci. 1974;19(1):1-15.
29. McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs. 1978;1(5):373-378.
30. Polit DF, Beck CT. Nursing Research Principles and Methods. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:289-314.
31. Thompson GN, Chochinov HM. Methodological challenges in measuring quality care at the end of life in the long-term care environment. J Pain Symp Manage. 2006;32(4):378-391.
32. Janssen-Heijnen MLG, von Spronsen DJ, Lemmons VEPP, Houterman S, Verheij KDGW, Coebergh JWW. A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: prognostic impact independent of international prognostic index. Br J Haematol. 2005;129:597-606.
33. Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med. 1999;13(4):299-310.
34. Curran P, Hussong A. The use of latent trajectory models in psychopathology research. J Abnorm Psychol. 2003;112:536-544.
35. Jo B. Estimation of intervention effects with non-compliance: alternative modeling specifications. J Educ Behav Stat. 2003;27:385-409.
36. Muthen B, Curran P. General longitudinal modeling of individual differences in experimental designs: a latent variable framework for analysis and power estimation. Psychol Methods. 1997;2:371-402.